查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球基因組學人工智能 (AI) 市場：按產品、技術、功能、應用、最終用戶、地區劃分——預測至 2028 年
市場調查報告書
商品編碼
1275429

全球基因組學人工智能 (AI) 市場：按產品、技術、功能、應用、最終用戶、地區劃分——預測至 2028 年

Artificial Intelligence In Genomics Market by Offering, Technology, Functionality, Application, End User - Global Forecasts to 2028
出版日期: | 出版商: MarketsandMarkets | 英文 240 Pages | 訂單完成後即時交付

價格
簡介目錄

用於基因組學的全球人工智能 (AI) 市場規模將從 2023 年的估計 5 億美元擴大到 2028 年的 20 億美元，複合年增長率為 32.3% 預計在預測期內增長。

由於更快的流程和時間表、更快的藥物發現和開發需求、更高的計算能力和更低的硬件成本等因素，該市場具有廣闊的增長潛力。. 然而，缺乏精選的基因組數據和對數據隱私的擔憂預計會在一定程度上限制該市場的增長。

“深度學習：機器學習在基因組市場人工智能 (AI) 中增長最快的部分”

在預測期內，深度學習部分預計增長最快。 深度學習方法在基因組學中主導計算建模策略，範圍從理解 DNA 序列的蛋白質結合、表觀遺傳修飾、從表觀遺傳標記預測基因表達，以及預測單細胞甲基化狀態，用於解決問題。 對加速基因組測序分析工作流程的需求不斷增長以及對基因編輯工具增強功能的需求預計將推動市場增長。

“在預測期內，按功能劃分，基因組測序領域預計將成為基因組學最大的人工智能 (AI) 市場”

按功能劃分，市場分為基因組測序、基因編輯、臨床工作流程以及預測性基因檢測和預防醫學。 基因組測序部分在基因組學市場的人工智能 (AI) 中佔有最大份額。 這一細分市場的很大一部分可歸因於使用人工智能解決方案來識別染色體疾病、畸形綜合徵、致畸性疾病和單基因疾病。

“在預測期內，歐洲將佔據基因組學人工智能 (AI) 市場的第二大份額”

在預測期內，歐洲在基因組學人工智能 (AI) 市場中佔據第二大份額。 推動市場增長的關鍵因素包括在基因組研究和藥物發現中越來越多地採用基於 AI 的工具、有利的政府舉措、越來越多的 EMR 採用、不斷增長的患者數據量、越來越多的風險投資資金、醫療保健成本上升和老年人口不斷增加。 此外，人工智能在推進研發活動方面的潛力也引起了該領域的關注。

內容

第一章介紹

第二章研究方法論

第 3 章執行摘要

第 4 章重要注意事項

第 5 章市場概述

  • 簡介
  • 市場動態
    • 司機
    • 約束因素
    • 機會
    • 任務
  • 生態系統分析

第 6 章基因組學人工智能 (AI) 市場：通過提供

  • 簡介
  • 軟件
  • 服務

第 7 章基因組學人工智能 (AI) 市場：按技術分類

  • 簡介
  • 機器學習
    • 深度學習
    • 監督學習
    • 強化學習
    • 無監督學習
    • 其他
  • 其他

第 8 章基因組學人工智能 (AI) 市場：按功能分類

  • 簡介
  • 基因組測序
  • 基因編輯
  • 臨床工作流程
  • 預測性基因檢測和預防醫學

第 9 章基因組學人工智能 (AI) 市場：按應用

  • 簡介
  • 診斷
  • 藥物發現和開發
  • 精準醫學
  • 農業和動物研究
  • 其他

第 10 章基因組學人工智能 (AI) 市場：按最終用戶分類

  • 簡介
  • 製藥和生物技術公司
  • 研究中心、學術機構、政府機構
  • 醫院和醫療保健提供者
  • 其他

第 11 章基因組學人工智能 (AI) 市場：按地區

  • 簡介
  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 其他歐洲
  • 亞太地區
  • 其他地區

第12章競爭格局

  • 概覽
  • 主要市場公司/有影響力公司的戰略
  • 頂級市場公司的收入份額分析（2022 年）
  • 市場排名分析 (2022)
  • 競爭基準
  • 主要公司的企業評估象限
  • 初創公司/中小企業的企業評估象限
  • 競爭情景和趨勢

第13章公司簡介

  • 主要公司
    • NVIDIA CORPORATION
    • MICROSOFT CORPORATION
    • GOOGLE, INC.
    • INTEL CORPORATION
    • BENEVOLENTAI
    • SOPHIA GENETICS
    • ILLUMINA, INC.
    • PREDICTIVE ONCOLOGY, INC.
    • INVITAE CORPORATION
    • DEEP GENOMICS, INC.
    • FABRIC GENOMICS, INC.
    • VERGE GENOMICS
    • FREENOME HOLDINGS, INC.
    • MOLECULARMATCH, INC.
    • DANTE LABS
    • DATA4CURE
    • PRECISIONLIFE LTD
    • GENOOX
    • LIFEBIT
  • 其他新興企業
    • FDNA, INC.
    • DNANEXUS
    • ENGINE BIOSCIENCES
    • TEMPUS LABS, INC.
    • CONGENICA LTD
    • EMEDGENE, INC.
    • SERAGON PHARMACEUTICALS, INC.

第14章 附錄

簡介目錄
Product Code: HIT 7852

The artificial intelligence (AI) in genomics market is anticipated to grow from an estimated USD 0.5 billion in 2023 to USD 2.0 billion in 2028, at a CAGR of 32.3% during the forecast period. The market has a promising growth potential due to the need to accelerate processes and timeline and reduce drug development and discovery, and improving computing power and declining hardware cost among other factors. However, the lack of curated genomic data and data privacy concerns are expected to limit the growth of this market to a certain extent.

"Deep learning: The fastest-growing segment of the artificial intelligence (AI) in genomics market for machine learning, by type"

The deep learning segment is expected to witness the fastest growth in the infection surveillance services market during the forecast. Deep learning methods have dominated computational modeling strategies in genomics, where they are used to address a variety of questions ranging from the understanding of protein binding from DNA sequences, epigenetic modifications, predicting gene expression from epigenetic marks, or predicting the methylation state of single cells. The growing demand for accelerated genome sequencing analysis workflows and the need to improve the function of gene editing tools is expected to propel market growth.

"The genome sequencing segment is anticipated to be the largest artificial intelligence (AI) in genomics market, by functionality, during the forecast period"

Based on functionality, the market is segmented into genome sequencing, gene editing, clinical workflows, and predictive genetic testing & preventive medicine. The genome sequencing segment accounted for the largest share of the artificial intelligence (AI) in genomics market. The large share of this segment can be attributed to the use of AI solutions to identify chromosomal disorders, dysmorphic syndromes, teratogenic disorders, and single-gene disorders.

"Europe accounted for the second-largest share in the artificial intelligence (AI) in genomics market during the forecast period"

Europe accounted for the second-largest share of the artificial intelligence (AI) in genomics market during the forecast period. The major drivers of market growth are the increasing adoption of AI-based tools in genomic research and drug discovery, favorable government initiatives, growing EMR adoption, increasing patient data volume, increasing venture capital funding, rising healthcare expenditure, and growing geriatric population. Moreover, the potential for AI in advancing R&D activities has also attracted attention to this sector.

Break of primary participants was as mentioned below:

  • By Company Type - Tier 1-40%, Tier 2-35%, and Tier 3-25%
  • By Designation - C-level-35%, Director-level-25%, Others-40%
  • By Region - North America-45%, Europe-30%, Asia Pacific-20%, and Rest of the World-5%

Key players in the Artificial intelligence (AI) in genomics Market

The key players operating in the artificial intelligence (AI) in genomics market include NVIDIA Corporation (US), Microsoft Corporation (US), Google, Inc. (US), Intel Corporation (US), BenevolentAI (UK), SOPHiA GENETICS (Switzerland), Illumina, Inc. (US), Predictive Oncology, Inc. (US), Invitae Corporation (US), Deep Genomics, Inc. (Canada), Fabric Genomics, Inc. (US), Verge Genomics (US), Freenome Holdings, Inc. (US), MolecularMatch, Inc. (US), Dante labs (US), Data4Cure (US), PrecisionLife Ltd (UK), Genoox (US), Lifebit (UK), FDNA, Inc. (US), DNAnexus (US), Engine Biosciences (US), Tempus Labs, Inc. (US), Congenica Ltd (England), Emedgene, Inc. (US), and Seragon Pharmaceuticals, Inc. (US).

Research Coverage:

The report analyzes the artificial intelligence (AI) in genomics market and aims at estimating the market size and future growth potential of this market based on various segments such as offering, technology, functionality, application, end user, and region. The report also includes a product portfolio matrix of various artificial intelligence (AI) in genomics products & services available in the market. The report also provides a competitive analysis of the key players in this market, along with their company profiles, product offerings, and key market strategies.

Reasons to Buy the Report

The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn would help them, garner a more significant share of the market. Firms purchasing the report could use one or any combination of the below-mentioned strategies to strengthen their position in the market.

This report provides insights into the following pointers:

  • Market Penetration: Comprehensive information on product portfolios offered by the top players in the global artificial intelligence (AI) in genomics market. The report analyzes this market by product & service and end user.
  • Product Enhancement/Innovation: Detailed insights on upcoming trends and product launches in the global artificial intelligence (AI) in genomics market
  • Market Development: Comprehensive information on the lucrative emerging markets by products & services and end user
  • Market Diversification: Exhaustive information about new products or product enhancements, growing geographies, recent developments, and investments in the global artificial intelligence (AI) in genomics market
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, competitive leadership mapping, and capabilities of leading players in the global artificial intelligence (AI) in genomics market.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
  • 1.3 INCLUSIONS AND EXCLUSIONS
  • 1.4 STUDY SCOPE
    • 1.4.1 MARKETS COVERED
    • FIGURE 1 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET SEGMENTATION
    • 1.4.2 REGIONS COVERED
  • 1.5 YEARS CONSIDERED
  • 1.6 CURRENCY CONSIDERED
    • TABLE 1 CURRENCY CONVERSION RATES
  • 1.7 LIMITATIONS
  • 1.8 STAKEHOLDERS
  • 1.9 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • FIGURE 2 RESEARCH DESIGN
    • FIGURE 3 RESEARCH APPROACH
    • 2.1.1 SECONDARY RESEARCH
      • 2.1.1.1 Key data from secondary sources
    • 2.1.2 PRIMARY RESEARCH
      • 2.1.2.1 Key primary sources
      • 2.1.2.2 Key data from primary sources
      • 2.1.2.3 Key industry insights
      • 2.1.2.4 Breakdown of primary interviews
    • FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
    • FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • 2.2 MARKET SIZE ESTIMATION
    • FIGURE 6 KEY METRICS FOR ASSESSING SUPPLY OF ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET
    • FIGURE 7 REVENUES GENERATED BY COMPANIES FROM SALE OF ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS SOLUTIONS
    • FIGURE 8 REVENUE SHARE ANALYSIS ILLUSTRATION
    • FIGURE 9 BOTTOM-UP APPROACH
    • FIGURE 10 ESTIMATION OF ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET SIZE BASED ON ADOPTION
    • FIGURE 11 TOP-DOWN APPROACH
    • TABLE 2 FACTOR ANALYSIS
  • 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
    • FIGURE 12 DATA TRIANGULATION METHODOLOGY
  • 2.4 RESEARCH ASSUMPTIONS
    • FIGURE 13 ASSUMPTIONS FOR RESEARCH STUDY
  • 2.5 IMPACT OF RECESSION
  • 2.6 RISK ASSESSMENT
    • TABLE 3 LIMITATIONS AND ASSOCIATED RISKS
  • 2.7 RESEARCH LIMITATIONS

3 EXECUTIVE SUMMARY

    • FIGURE 14 SOFTWARE SEGMENT TO LEAD ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY OFFERING
    • FIGURE 15 MACHINE LEARNING CONTINUES TO ACQUIRE LARGEST SIZE OF ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY TECHNOLOGY
    • FIGURE 16 DEEP LEARNING TO BE FASTEST-GROWING SEGMENT OF ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET FOR MACHINE LEARNING
    • FIGURE 17 GENOME SEQUENCING TO REGISTER HIGHEST CAGR IN ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY FUNCTIONALITY
    • FIGURE 18 DIAGNOSTICS TO DOMINATE ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY APPLICATION
    • FIGURE 19 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO SECURE LEADING POSITION IN ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY END USER
    • FIGURE 20 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION

4 PREMIUM INSIGHTS

  • 4.1 ATTRACTIVE OPPORTUNITIES FOR PLAYERS IN ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET
    • FIGURE 21 INCREASING ADOPTION OF ARTIFICIAL INTELLIGENCE (AI) SOLUTIONS FOR DRUG DISCOVERY & DEVELOPMENT AND PRECISION MEDICINE TO DRIVE MARKET
  • 4.2 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION
    • FIGURE 22 NORTH AMERICA TO DOMINATE ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET DURING FORECAST PERIOD
  • 4.3 NORTH AMERICAN ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY END USER AND COUNTRY, 2022
    • FIGURE 23 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES AND US DOMINATED MARKET IN NORTH AMERICA IN 2022
  • 4.4 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY OFFERING
    • FIGURE 24 SOFTWARE SEGMENT TO HOLD MAJORITY MARKET SHARE IN 2028
  • 4.5 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY TECHNOLOGY
    • FIGURE 25 MACHINE LEARNING TO SURPASS OTHER TECHNOLOGIES IN 2028
  • 4.6 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY END USER
    • FIGURE 26 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO ACCOUNT FOR LARGEST MARKET SHARE IN 2028
  • 4.7 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY FUNCTIONALITY
    • FIGURE 27 GENOME SEQUENCING TO BE FASTEST-GROWING SEGMENT DURING FORECAST PERIOD
  • 4.8 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY APPLICATION
    • FIGURE 28 DIAGNOSTICS TO DOMINATE MARKET IN 2028

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • 5.2.1 DRIVERS
      • 5.2.1.1 Need to accelerate processes and timeline and reduce drug development & discovery costs
      • 5.2.1.2 Increased partnerships and collaborations among players and growing investments in AI in genomics
      • 5.2.1.3 Rising adoption of AI in precision medicine
      • 5.2.1.4 Explosion in bioinformatics data and genomic datasets
    • FIGURE 29 COST OF GENOME ANALYSIS VS. LEVELS OF RAW DATA GENERATED, 2003-2023
      • 5.2.1.5 Improving computing power and declining hardware cost
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 Lack of skilled AI workforce and ambiguous regulatory guidelines for medical software
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Focus on developing human-aware AI systems
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Lack of curated genomic data
      • 5.2.4.2 Data privacy concerns
    • FIGURE 30 HEALTHCARE BREACHES REPORTED TO US DEPARTMENT OF HEALTH AND HUMAN SERVICES, 2019-2021
  • 5.3 ECOSYSTEM ANALYSIS
    • FIGURE 31 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET: ECOSYSTEM ANALYSIS

6 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY OFFERING

  • 6.1 INTRODUCTION
    • FIGURE 32 SOFTWARE SEGMENT ACCOUNTED FOR LARGER MARKET SHARE IN 2022
    • TABLE 4 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY OFFERING, 2021-2028 (USD MILLION)
  • 6.2 SOFTWARE
    • 6.2.1 INTELLIGENT SOFTWARE TO REDUCE ERRORS CAUSED BY STANDARD STATISTICAL APPROACHES
    • TABLE 5 SOFTWARE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 6 SOFTWARE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN NORTH AMERICA, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 7 SOFTWARE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN EUROPE, BY COUNTRY, 2021-2028 (USD MILLION)
  • 6.3 SERVICES
    • 6.3.1 RISING AI TECHNOLOGY ADOPTION IN VARIOUS END-USE INDUSTRIES TO BOOST MARKET
    • TABLE 8 SERVICES: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 9 SERVICES: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN NORTH AMERICA, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 10 SERVICES: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN EUROPE, BY COUNTRY, 2021-2028 (USD MILLION)

7 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY TECHNOLOGY

  • 7.1 INTRODUCTION
    • FIGURE 33 MACHINE LEARNING SEGMENT ACCOUNTED FOR LARGER MARKET SHARE IN 2022
    • TABLE 11 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • 7.2 MACHINE LEARNING
    • FIGURE 34 DEEP LEARNING SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2022
    • TABLE 12 MACHINE LEARNING: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 13 MACHINE LEARNING: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 14 MACHINE LEARNING: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN NORTH AMERICA, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 15 MACHINE LEARNING: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN EUROPE, BY COUNTRY, 2021-2028 (USD MILLION)
    • 7.2.1 DEEP LEARNING
      • 7.2.1.1 Growing demand for accelerated genome sequencing analysis workflows and improved function of gene editing tools to propel market
    • TABLE 16 DEEP LEARNING: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 17 DEEP LEARNING: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN NORTH AMERICA, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 18 DEEP LEARNING: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN EUROPE, BY COUNTRY, 2021-2028 (USD MILLION)
    • 7.2.2 SUPERVISED LEARNING
      • 7.2.2.1 To help create predictive models for population health management
    • TABLE 19 SUPERVISED LEARNING: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 20 SUPERVISED LEARNING: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN NORTH AMERICA, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 21 SUPERVISED LEARNING: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN EUROPE, BY COUNTRY, 2021-2028 (USD MILLION)
    • 7.2.3 REINFORCEMENT LEARNING
      • 7.2.3.1 Need to reduce costs associated with collecting labeled training data to drive segment
    • TABLE 22 REINFORCEMENT LEARNING: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 23 REINFORCEMENT LEARNING: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN NORTH AMERICA, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 24 REINFORCEMENT LEARNING: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN EUROPE, BY COUNTRY, 2021-2028 (USD MILLION)
    • 7.2.4 UNSUPERVISED LEARNING
      • 7.2.4.1 Ability to perform more complex processing tasks than supervised learning systems to drive market
    • TABLE 25 UNSUPERVISED LEARNING: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 26 UNSUPERVISED LEARNING: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN NORTH AMERICA, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 27 UNSUPERVISED LEARNING: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN EUROPE, BY COUNTRY, 2021-2028 (USD MILLION)
    • 7.2.5 OTHER MACHINE LEARNING TECHNOLOGIES
    • TABLE 28 OTHER MACHINE LEARNING TECHNOLOGIES: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 29 OTHER MACHINE LEARNING TECHNOLOGIES: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN NORTH AMERICA, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 30 OTHER MACHINE LEARNING TECHNOLOGIES: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN EUROPE, BY COUNTRY, 2021-2028 (USD MILLION)
  • 7.3 OTHER TECHNOLOGIES
    • TABLE 31 OTHER TECHNOLOGIES: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 32 OTHER TECHNOLOGIES: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN NORTH AMERICA, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 33 OTHER TECHNOLOGIES: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN EUROPE, BY COUNTRY, 2021-2028 (USD MILLION)

8 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY FUNCTIONALITY

  • 8.1 INTRODUCTION
    • FIGURE 35 GENOME SEQUENCING SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2022
    • TABLE 34 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY FUNCTIONALITY, 2021-2028 (USD MILLION)
  • 8.2 GENOME SEQUENCING
    • 8.2.1 INCREASING ADOPTION OF MACHINE AND DEEP LEARNING IN DIAGNOSTICS AND DRUG DISCOVERY PROCESSES TO ENHANCE MARKET GROWTH
    • TABLE 35 GENOME SEQUENCING: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 36 GENOME SEQUENCING: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN NORTH AMERICA, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 37 GENOME SEQUENCING: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN EUROPE, BY COUNTRY, 2021-2028 (USD MILLION)
  • 8.3 GENE EDITING
    • 8.3.1 TO HELP IMPROVE GENE EDITING FUNCTIONS AND REDUCE TIME AND COSTS
    • TABLE 38 GENE EDITING: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 39 GENE EDITING: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN NORTH AMERICA, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 40 GENE EDITING: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN EUROPE, BY COUNTRY, 2021-2028 (USD MILLION)
  • 8.4 CLINICAL WORKFLOW
    • 8.4.1 TO HELP INCREASE EFFICIENCY OF CLINICAL WORKFLOWS
    • TABLE 41 CLINICAL WORKFLOW: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 42 CLINICAL WORKFLOW: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN NORTH AMERICA, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 43 CLINICAL WORKFLOW: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN EUROPE, BY COUNTRY, 2021-2028 (USD MILLION)
  • 8.5 PREDICTIVE GENETIC TESTING & PREVENTIVE MEDICINE
    • 8.5.1 AI IN GENOMICS TO PREDICT OUTCOMES AND RISKS ASSOCIATED WITH CURING GENETIC DISEASES BASED ON AVAILABLE DATA
    • TABLE 44 PREDICTIVE GENETIC TESTING & PREVENTIVE MEDICINE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 45 PREDICTIVE GENETIC TESTING & PREVENTIVE MEDICINE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN NORTH AMERICA, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 46 PREDICTIVE GENETIC TESTING & PREVENTIVE MEDICINE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN EUROPE, BY COUNTRY, 2021-2028 (USD MILLION)

9 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY APPLICATION

  • 9.1 INTRODUCTION
    • FIGURE 36 DIAGNOSTICS SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2022
    • TABLE 47 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • 9.2 DIAGNOSTICS
    • 9.2.1 AI IN GENOMICS FOR DIAGNOSTICS TO HELP IDENTIFY CHROMOSOMAL DISORDERS, DYSMORPHIC SYNDROMES, TERATOGENIC DISORDERS, AND SINGLE-GENE DISORDERS
    • TABLE 48 INDICATIVE LIST OF DEVELOPMENTS FOR DIAGNOSTICS APPLICATION
    • TABLE 49 DIAGNOSTICS: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 50 DIAGNOSTICS: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN NORTH AMERICA, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 51 DIAGNOSTICS: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN EUROPE, BY COUNTRY, 2021-2028 (USD MILLION)
  • 9.3 DRUG DISCOVERY & DEVELOPMENT
    • 9.3.1 GROWING APPLICATION OF AI IN GENOMICS IN DRUG DISCOVERY & DEVELOPMENT TO PROPEL MARKET
    • TABLE 52 INDICATIVE LIST OF DEVELOPMENTS FOR DRUG DELIVERY & DISCOVERY APPLICATION
    • TABLE 53 DRUG DISCOVERY & DEVELOPMENT: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 54 DRUG DISCOVERY & DEVELOPMENT: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN NORTH AMERICA, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 55 DRUG DISCOVERY & DEVELOPMENT: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN EUROPE, BY COUNTRY, 2021-2028 (USD MILLION)
  • 9.4 PRECISION MEDICINE
    • 9.4.1 FOCUSE ON IDENTIFYING EFFECTIVE MEDICAL TREATMENTS FOR PATIENTS TO DRIVE MARKET
    • TABLE 56 INDICATIVE LIST OF DEVELOPMENTS FOR PRECISION MEDICINE APPLICATION
    • TABLE 57 PRECISION MEDICINE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 58 PRECISION MEDICINE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN NORTH AMERICA, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 59 PRECISION MEDICINE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN EUROPE, BY COUNTRY, 2021-2028 (USD MILLION)
  • 9.5 AGRICULTURE & ANIMAL RESEARCH
    • 9.5.1 AI IN GENOMICS TO HELP IMPROVE CROP AND LIVESTOCK PRODUCTIVITY
    • TABLE 60 AGRICULTURE & ANIMAL RESEARCH: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 61 AGRICULTURE & ANIMAL RESEARCH: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN NORTH AMERICA, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 62 AGRICULTURE & ANIMAL RESEARCH: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN EUROPE, BY COUNTRY, 2021-2028 (USD MILLION)
  • 9.6 OTHER APPLICATIONS
    • TABLE 63 OTHER APPLICATIONS: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 64 OTHER APPLICATIONS: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN NORTH AMERICA, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 65 OTHER APPLICATIONS: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN EUROPE, BY COUNTRY, 2021-2028 (USD MILLION)

10 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY END USER

  • 10.1 INTRODUCTION
    • FIGURE 37 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES ACCOUNTED FOR LARGEST MARKET SHARE IN 2022
    • TABLE 66 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
    • 10.2.1 RISING DEMAND FOR SOLUTIONS TO REDUCE TIME AND COSTS OF DRUG DEVELOPMENT
    • TABLE 67 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES: INDICATIVE DEVELOPMENTS
    • TABLE 68 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 69 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN NORTH AMERICA, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 70 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN EUROPE, BY COUNTRY, 2021-2028 (USD MILLION)
  • 10.3 RESEARCH CENTERS, ACADEMIC INSTITUTES, AND GOVERNMENT ORGANIZATIONS
    • 10.3.1 INCREASED RESEARCH ACTIVITIES TO ENCOURAGE USE OF AI IN GENOMICS IN ACADEMIC AND GOVERNMENT INSTITUTES
    • TABLE 71 RESEARCH CENTERS, ACADEMIC INSTITUTES, AND GOVERNMENT ORGANIZATIONS: INDICATIVE DEVELOPMENTS
    • TABLE 72 RESEARCH CENTERS, ACADEMIC INSTITUTES, AND GOVERNMENT ORGANIZATIONS: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 73 RESEARCH CENTERS, ACADEMIC INSTITUTES, AND GOVERNMENT ORGANIZATIONS: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN NORTH AMERICA, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 74 RESEARCH CENTERS, ACADEMIC INSTITUTES, AND GOVERNMENT ORGANIZATIONS: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN EUROPE, BY COUNTRY, 2021-2028 (USD MILLION)
  • 10.4 HOSPITALS & HEALTHCARE PROVIDERS
    • 10.4.1 GROWING DEMAND FOR PHARMACOGENOMICS TO PROPEL ACCEPTANCE OF NGS IN HOSPITALS
    • TABLE 75 HOSPITALS & HEALTHCARE PROVIDERS: INDICATIVE DEVELOPMENTS
    • TABLE 76 HOSPITALS & HEALTHCARE PROVIDERS: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 77 HOSPITALS & HEALTHCARE PROVIDERS: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN NORTH AMERICA, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 78 HOSPITALS & HEALTHCARE PROVIDERS: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN EUROPE, BY COUNTRY, 2021-2028 (USD MILLION)
  • 10.5 OTHER END USERS
    • TABLE 79 OTHER END USERS: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 80 OTHER END USERS: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN NORTH AMERICA, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 81 OTHER END USERS: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN EUROPE, BY COUNTRY, 2021-2028 (USD MILLION)

11 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION

  • 11.1 INTRODUCTION
    • FIGURE 38 ASIA PACIFIC TO EMERGE AS NEW HOTSPOT DURING FORECAST PERIOD
    • FIGURE 39 NORTH AMERICA ACCOUNTED FOR LARGEST MARKET SHARE IN 2022
    • TABLE 82 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION, 2021-2028 (USD MILLION)
  • 11.2 NORTH AMERICA
    • 11.2.1 NORTH AMERICA: RECESSION IMPACT
    • FIGURE 40 NORTH AMERICA: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET SNAPSHOT
    • TABLE 83 NORTH AMERICA: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 84 NORTH AMERICA: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY OFFERING, 2021-2028 (USD MILLION)
    • TABLE 85 NORTH AMERICA: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 86 NORTH AMERICA: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET FOR MACHINE LEARNING, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 87 NORTH AMERICA: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY FUNCTIONALITY, 2021-2028 (USD MILLION)
    • TABLE 88 NORTH AMERICA: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 89 NORTH AMERICA: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.2.2 US
      • 11.2.2.1 Initiatives to accelerate genomic research and growing adoption of AI to bolster market
    • TABLE 90 US: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY OFFERING, 2021-2028 (USD MILLION)
    • TABLE 91 US: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 92 US: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET FOR MACHINE LEARNING, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 93 US: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY FUNCTIONALITY, 2021-2028 (USD MILLION)
    • TABLE 94 US: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 95 US: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.2.3 CANADA
      • 11.2.3.1 Increasing research in genomics to drive market
    • TABLE 96 CANADA: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY OFFERING, 2021-2028 (USD MILLION)
    • TABLE 97 CANADA: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 98 CANADA: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET FOR MACHINE LEARNING, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 99 CANADA: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY FUNCTIONALITY, 2021-2028 (USD MILLION)
    • TABLE 100 CANADA: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 101 CANADA: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 11.3 EUROPE
    • 11.3.1 EUROPE: RECESSION IMPACT
    • TABLE 102 EUROPE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 103 EUROPE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY OFFERING, 2021-2028 (USD MILLION)
    • TABLE 104 EUROPE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 105 EUROPE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET FOR MACHINE LEARNING, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 106 EUROPE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY FUNCTIONALITY, 2021-2028 (USD MILLION)
    • TABLE 107 EUROPE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 108 EUROPE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.3.2 UK
      • 11.3.2.1 Adoption of AI in genomics for drug discovery to fuel market
    • TABLE 109 UK: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY OFFERING, 2021-2028 (USD MILLION)
    • TABLE 110 UK: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 111 UK: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET FOR MACHINE LEARNING, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 112 UK: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY FUNCTIONALITY, 2021-2028 (USD MILLION)
    • TABLE 113 UK: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 114 UK: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.3.3 GERMANY
      • 11.3.3.1 Availability of funding for AI initiatives to boost market
    • TABLE 115 GERMANY: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY OFFERING, 2021-2028 (USD MILLION)
    • TABLE 116 GERMANY: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 117 GERMANY: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET FOR MACHINE LEARNING, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 118 GERMANY: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY FUNCTIONALITY, 2021-2028 (USD MILLION)
    • TABLE 119 GERMANY: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 120 GERMANY: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.3.4 FRANCE
      • 11.3.4.1 Increasing government investments in NGS to boost market
    • TABLE 121 FRANCE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY OFFERING, 2021-2028 (USD MILLION)
    • TABLE 122 FRANCE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 123 FRANCE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET FOR MACHINE LEARNING, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 124 FRANCE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY FUNCTIONALITY, 2021-2028 (USD MILLION)
    • TABLE 125 FRANCE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 126 FRANCE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.3.5 REST OF EUROPE
    • TABLE 127 REST OF EUROPE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY OFFERING, 2021-2028 (USD MILLION)
    • TABLE 128 REST OF EUROPE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 129 REST OF EUROPE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET FOR MACHINE LEARNING, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 130 REST OF EUROPE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY FUNCTIONALITY, 2021-2028 (USD MILLION)
    • TABLE 131 REST OF EUROPE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 132 REST OF EUROPE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 11.4 ASIA PACIFIC
    • 11.4.1 ASIA PACIFIC: RECESSION IMPACT
    • FIGURE 41 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET SNAPSHOT
    • TABLE 133 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY OFFERING, 2021-2028 (USD MILLION)
    • TABLE 134 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 135 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET FOR MACHINE LEARNING, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 136 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY FUNCTIONALITY, 2021-2028 (USD MILLION)
    • TABLE 137 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 138 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 11.5 REST OF THE WORLD
    • 11.5.1 REST OF THE WORLD: RECESSION IMPACT
    • TABLE 139 REST OF THE WORLD: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY OFFERING, 2021-2028 (USD MILLION)
    • TABLE 140 REST OF THE WORLD: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 141 REST OF THE WORLD: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET FOR MACHINE LEARNING, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 142 REST OF THE WORLD: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY FUNCTIONALITY, 2021-2028 (USD MILLION)
    • TABLE 143 REST OF THE WORLD: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 144 REST OF THE WORLD: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY END USER, 2021-2028 (USD MILLION)

12 COMPETITIVE LANDSCAPE

  • 12.1 OVERVIEW
  • 12.2 KEY MARKET PLAYERS' STRATEGIES/RIGHT TO WIN
    • TABLE 145 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET
    • FIGURE 42 KEY DEVELOPMENTS BY MAJOR MARKET PLAYERS BETWEEN JANUARY 2020 AND MARCH 2023
  • 12.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS, 2022
    • FIGURE 43 REVENUE SHARE ANALYSIS OF KEY MARKET PLAYERS, 2022
  • 12.4 MARKET RANKING ANALYSIS, 2022
    • FIGURE 44 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET SHARE ANALYSIS, 2022
  • 12.5 COMPETITIVE BENCHMARKING
    • TABLE 146 COMPANY FOOTPRINT ANALYSIS
    • TABLE 147 PRODUCT FOOTPRINT ANALYSIS (26 COMPANIES)
    • TABLE 148 FUNCTIONALITY FOOTPRINT ANALYSIS (26 COMPANIES)
    • TABLE 149 REGIONAL FOOTPRINT ANALYSIS (26 COMPANIES)
  • 12.6 COMPANY EVALUATION QUADRANT FOR KEY PLAYERS
    • 12.6.1 STARS
    • 12.6.2 PERVASIVE PLAYERS
    • 12.6.3 EMERGING LEADERS
    • 12.6.4 PARTICIPANTS
    • FIGURE 45 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET: COMPANY EVALUATION QUADRANT FOR KEY PLAYERS, 2022
  • 12.7 COMPANY EVALUATION QUADRANT FOR START-UPS/SMES
    • 12.7.1 PROGRESSIVE COMPANIES
    • 12.7.2 DYNAMIC COMPANIES
    • 12.7.3 RESPONSIVE COMPANIES
    • 12.7.4 STARTING BLOCKS
    • FIGURE 46 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET: COMPANY EVALUATION QUADRANT FOR START-UPS/SMES, 2022
  • 12.8 COMPETITIVE SCENARIOS AND TRENDS
    • 12.8.1 PRODUCT LAUNCHES/ENHANCEMENTS
    • TABLE 150 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET: PRODUCT LAUNCHES/ENHANCEMENTS, 2020-2023
    • 12.8.2 DEALS
    • TABLE 151 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET: DEALS, 2020-2023
    • 12.8.3 OTHER DEVELOPMENTS
    • TABLE 152 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET: OTHER DEVELOPMENTS, 2020-2023

13 COMPANY PROFILES

  • 13.1 KEY PLAYERS

(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))**

    • 13.1.1 NVIDIA CORPORATION
    • TABLE 153 NVIDIA CORPORATION: COMPANY OVERVIEW
    • FIGURE 47 NVIDIA CORPORATION: COMPANY SNAPSHOT
    • TABLE 154 NVIDIA CORPORATION: PRODUCTS/SERVICES OFFERED
    • TABLE 155 NVIDIA CORPORATION: PRODUCT LAUNCHES/ENHANCEMENTS
    • TABLE 156 NVIDIA CORPORATION: DEALS
    • 13.1.2 MICROSOFT CORPORATION
    • TABLE 157 MICROSOFT CORPORATION: COMPANY OVERVIEW
    • FIGURE 48 MICROSOFT CORPORATION: COMPANY SNAPSHOT
    • TABLE 158 MICROSOFT CORPORATION: PRODUCTS/SERVICES OFFERED
    • TABLE 159 MICROSOFT CORPORATION: DEALS
    • 13.1.3 GOOGLE, INC.
    • TABLE 160 GOOGLE, INC.: COMPANY OVERVIEW
    • FIGURE 49 GOOGLE, INC.: COMPANY SNAPSHOT, 2022
    • TABLE 161 GOOGLE, INC.: PRODUCTS/SERVICES OFFERED
    • TABLE 162 GOOGLE, INC.: PRODUCT LAUNCHES/ENHANCEMENTS
    • TABLE 163 GOOGLE, INC.: DEALS
    • 13.1.4 INTEL CORPORATION
    • TABLE 164 INTEL CORPORATION: COMPANY OVERVIEW
    • FIGURE 50 INTEL CORPORATION: COMPANY SNAPSHOT
    • TABLE 165 INTEL CORPORATION: PRODUCTS/SERVICES OFFERED
    • TABLE 166 INTEL CORPORATION: PRODUCT LAUNCHES/ENHANCEMENTS
    • TABLE 167 INTEL CORPORATION: DEALS
    • 13.1.5 BENEVOLENTAI
    • TABLE 168 BENEVOLENTAI: COMPANY OVERVIEW
    • FIGURE 51 BENEVOLENTAI: COMPANY SNAPSHOT
    • TABLE 169 BENEVOLENTAI: PRODUCTS/SERVICES OFFERED
    • TABLE 170 BENEVOLENTAI: DEALS
    • 13.1.6 SOPHIA GENETICS
    • TABLE 171 SOPHIA GENETICS: COMPANY OVERVIEW
    • FIGURE 52 SOPHIA GENETICS: COMPANY SNAPSHOT
    • TABLE 172 SOPHIA GENETICS: PRODUCTS/SERVICES OFFERED
    • TABLE 173 SOPHIA GENOMICS: DEALS
    • TABLE 174 SOPHIA GENETICS: OTHERS
    • 13.1.7 ILLUMINA, INC.
    • TABLE 175 ILLUMINA, INC.: COMPANY OVERVIEW
    • FIGURE 53 ILLUMINA, INC.: COMPANY SNAPSHOT
    • TABLE 176 ILLUMINA, INC.: PRODUCTS/SERVICES OFFERED
    • TABLE 177 ILLUMINA, INC.: PRODUCT LAUNCHES/ENHANCEMENTS
    • TABLE 178 ILLUMINA, INC.: DEALS
    • 13.1.8 PREDICTIVE ONCOLOGY, INC.
    • TABLE 179 PREDICTIVE ONCOLOGY, INC.: COMPANY OVERVIEW
    • FIGURE 54 PREDICTIVE ONCOLOGY, INC.: COMPANY SNAPSHOT
    • TABLE 180 PREDICTIVE ONCOLOGY, INC.: PRODUCTS/SERVICES OFFERED
    • TABLE 181 PREDICTIVE ONCOLOGY, INC.: DEALS
    • 13.1.9 INVITAE CORPORATION
    • TABLE 182 INVITAE CORPORATION: COMPANY OVERVIEW
    • FIGURE 55 INVITAE CORPORATION: COMPANY SNAPSHOT, 2022
    • TABLE 183 INVITAE CORPORATION: PRODUCTS/SERVICES OFFERED
    • 13.1.10 DEEP GENOMICS, INC.
    • TABLE 184 DEEP GENOMICS, INC.: COMPANY OVERVIEW
    • TABLE 185 DEEP GENOMICS, INC.: PRODUCTS/SERVICES OFFERED
    • TABLE 186 DEEP GENOMICS, INC.: DEALS
    • TABLE 187 DEEP GENOMICS, INC.: OTHERS
    • 13.1.11 FABRIC GENOMICS, INC.
    • TABLE 188 FABRIC GENOMICS, INC.: COMPANY OVERVIEW
    • TABLE 189 FABRIC GENOMICS, INC.: PRODUCTS/SERVICES OFFERED
    • TABLE 190 FABRIC GENOMICS, INC.: PRODUCT LAUNCHES/ENHANCEMENTS
    • TABLE 191 FABRIC GENOMICS, INC.: DEALS
    • 13.1.12 VERGE GENOMICS
    • TABLE 192 VERGE GENOMICS: COMPANY OVERVIEW
    • TABLE 193 VERGE GENOMICS: PRODUCTS/SERVICES OFFERED
    • TABLE 194 VERGE GENOMICS: DEALS
    • 13.1.13 FREENOME HOLDINGS, INC.
    • TABLE 195 FREENOME HOLDINGS, INC.: COMPANY OVERVIEW
    • TABLE 196 FREENOME HOLDINGS, INC.: PRODUCTS/SERVICES OFFERED
    • TABLE 197 FREENOME HOLDINGS, INC.: DEALS
    • 13.1.14 MOLECULARMATCH, INC.
    • TABLE 198 MOLECULARMATCH, INC.: COMPANY OVERVIEW
    • TABLE 199 MOLECULARMATCH, INC.: PRODUCTS/SERVICES OFFERED
    • 13.1.15 DANTE LABS
    • TABLE 200 DANTE LABS: COMPANY OVERVIEW
    • TABLE 201 DANTE LABS: PRODUCTS/SERVICES OFFERED
    • TABLE 202 DANTE LABS: PRODUCT LAUNCHES/ENHANCEMENTS
    • TABLE 203 DANTE LABS: DEALS
    • 13.1.16 DATA4CURE
    • TABLE 204 DATA4CURE: COMPANY OVERVIEW
    • TABLE 205 DATA4CURE: PRODUCTS/SERVICES OFFERED
    • 13.1.17 PRECISIONLIFE LTD
    • TABLE 206 PRECISIONLIFE LTD: COMPANY OVERVIEW
    • TABLE 207 PRECISIONLIFE LTD: PRODUCTS/SERVICES OFFERED
    • TABLE 208 PRECISIONLIFE LTD: DEALS
    • 13.1.18 GENOOX
    • TABLE 209 GENOOX: COMPANY OVERVIEW
    • TABLE 210 GENOOX: PRODUCTS/SERVICES OFFERED
    • TABLE 211 GENOOX: DEALS
    • 13.1.19 LIFEBIT
    • TABLE 212 LIFEBIT: COMPANY OVERVIEW
    • TABLE 213 LIFEBIT: PRODUCTS/SERVICES OFFERED
    • TABLE 214 LIFEBIT: DEALS
    • TABLE 215 LIFEBIT: OTHERS
  • 13.2 OTHER EMERGING PLAYERS
    • 13.2.1 FDNA, INC.
    • 13.2.2 DNANEXUS
    • 13.2.3 ENGINE BIOSCIENCES
    • 13.2.4 TEMPUS LABS, INC.
    • 13.2.5 CONGENICA LTD
    • 13.2.6 EMEDGENE, INC.
    • 13.2.7 SERAGON PHARMACEUTICALS, INC.
  • *Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

14 APPENDIX

  • 14.1 DISCUSSION GUIDE
  • 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 14.3 CUSTOMIZATION OPTIONS
  • 14.4 RELATED REPORTS
  • 14.5 AUTHOR DETAILS